A prospective study of the pharmacokinetics of itraconazole solution was performed in 11 patients who underwent allogeneic BMT (day of BMT = day 0) after a conditioning regimen including total body irradiation (TBI). Itraconazole solution (400 mg once a day) was given 7 days before BMT and continued up to the end of neutropenia unless another antifungal treatment was necessary. Blood samples were collected before itraconazole intake (C min ) and 4 h later (C max ) every other day for assays of itraconazole (ITRA) and its active metabolite hydroxy-itraconazole (OH-ITRA). The mean values of C min ITRA and OH-ITRA, respectively, were 287 ؎ 109 ng/ml and 629 ؎ 227 ng/ml at day ؊1 and 378 ؎ 147 ng/ml and 725 ؎ 242 ng/ml at day +1. The maximum C min values were observed at day +3. Six patients at day ؊1 (54%) and 8 at day +1 (72%) had satisfactory residual plasma concentrations of at least 250 ng/ml of unchanged ITRA. From day +1 to day +9, eight patients discontinued the itraconazole treatment, five of them had satisfactory plasma residual concentrations at this time. This work shows a good bioavailability of itraconazole oral solution during the early phase after allogeneic BMT, but more data are needed for the late phases. Keywords: pharmacokinetics; itraconazole solution; BMT; TBI Prophylaxis and treatment of systemic fungal infections in patients undergoing allogeneic bone marrow transplant (BMT) remain important issues. Broad spectrum antifungals with a low toxicity and good bioavailability are being sought. Ideally, orally administered medications given to prevent invasive aspergillosis should provide a systemic effect. However several factors are likely to impair bioavailability of orally administered medications in allogeneic BMT patients: nausea and vomiting mainly during conditioning regimen period, mucositis during aplasia and acute graft-versus-host disease (GVHD) later.
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Itraconazole, a triazole broad spectrum antifungal 1,2 is presently marketed as capsules. Important variations in plasma itraconazole concentrations observed in patients, compared with healthy volunteers, 3 are related to individual conditions of drug absorption, thereby justifying plasma measurements. A plasma concentration of unchanged itraconazole (ITRA) у250 ng/ml is considered necessary to obtain a therapeutic effect on Aspergillus. 4 However, since hydroxy-itraconazole (OH-ITRA) has a similar antifungal effect to unchanged ITRA, 5 the active fraction is represented by the sum of unchanged ITRA and its active metabolite OH-ITRA with an effective total level of about 1000 ng equivalents/ml. This effective level could be estimated from the effective plasma levels of unchanged ITRA (Ϸ250 ng/ml) 4, 6 and metabolic ratio in human plasma between ITRA and OH-ITRA ([OH-ITRA]/[ITRA] Ϸ2).
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However the capsule formulation is of limited use in allogeneic BMT: its bioavailability is reduced when administered under fasting conditions and when coadministered with antacids. 8 Itraconazole oral solution is a new formulation where ITRA is solubilized in an aqueous solution via a hydroxypropyl-␤-cyclodextrin vehicle. This formulation allows higher bioavailability than the capsule formulation, as demonstrated in healthy volunteers (J Barone, RH Bierman, Janssen Research Foundation, data on file) and, conversely is better absorbed under fasting conditions. 9 Moreover, this formulation is expected to be less sensitive to reduced gastric acidity.
To determine whether itraconazole oral solution would be of benefit in seriously ill patients who are not able to ingest adequate quantities of food we performed a prospective study of pharmacokinetics of itraconazole solution in 11 patients who underwent allogeneic BMT after a conditioning regimen including a total body irradiation (TBI).
Patients and methods
After approval by the ethical committee, adult patients who had undergone allogeneic BMT from HLA-identical sibling donors after a conditioning regimen including TBI were enrolled in the study. Patients had to give written informed consent. Patients who had received known inhibiting or inducing concomitant medications to itraconazole 2 weeks prior to initiation of the trial were not included in the study. In the same manner patients requiring these same concomitant medications during the trial had to be withdrawn as well as patients with abnormal liver (alanine amino-transferase (ALAT), aspartate amino-transferase (ASAT) у twice the normal range) and abnormal renal function tests (serum creatinine у150 m). Antacids and anti-H2 medications allowed during the study were limited to ranitidine, aluminium hydroxyde and omeprazole. Itraconazole oral solution (Janssen-Cilag, France) was administered at a fixed dose of 400 mg once a day just after a light breakfast. Treatment was always initiated before the conditioning regimen, 7 days before day 0 (day of transplant). It was continued up to the end of neutropenia (neutrophils Ͼ0.5 × 10 9 /l) unless amphotericin B i.v. was necessary. During itraconazole treatment, compliance for itraconazole and occurrence of side-effects were noted daily. Vomiting, diarrhea, mucositis and other complications after transplant including acute GVHD were evaluated.
For the itraconazole pharmacokinetic studies, venous blood samples were taken on alternate days during the treatment period, starting 7 days before BMT, on the first day of itraconazole treatment, (Ϫ7, Ϫ5, Ϫ3, Ϫ1 days before BMT, +1, +3, +5, +7, +9 % days after BMT) up to the end of the treatment. On those days, two samples were taken: one before itraconazole intake (minimum concentration = C min ) and one 4 h later (maximum concentration = C max ), corresponding to the peak. 7 Plasma samples were assayed for ITRA and its active metabolite OH-ITRA by a reverse phase HPLC method. 10 The lower limit of quantification was 50 ng/ml. The interassay coefficients of variation were 6.3% and 8.6% over a range of concentration from 50 to 2000 ng/ml for ITRA and OH-ITRA, respectively.
Results
Eleven patients (seven males and four females) were enrolled in the study. Their characteristics are described in Table 1 . Underlying diseases were either multiple myeloma (MM) (four patients), myelodysplasia (MDS) (one patient), acute lymphoblastic leukemia (ALL) (three patients), acute myeloblastic leukemia (AML) (two patients) and chronic myeloid leukemia in blast crisis (CML-BC) (one patient). All patients received fractionated TBI (12 Gy) as the conditioning regimen with cyclophosphamide (60 mg/kg/day × 2 days) or with cyclophosphamide (120 mg/kg) and melphalan (70 mg/m 2 ). Mean age was 34 years (range 20-49) and mean weight 68 kg (range 47-90). Patients received itraconazole solution at a fixed dose of 400 mg/day (ranging from 4.4 to 8.5 mg/kg/day according to the weight of each patient) for 9 to 32 days.
Three different phases were considered: pretransplant phase (from day Ϫ7 to day Ϫ1) and two post-transplant phases (from day +1 to day +7 and from day +7 to day +21).
Treatment was discontinued before the end of neutropenia in eight patients: five patients because of amphotericin B i.v. treatment and three patients because of other causes (one poor gastric tolerance, one transfer in intensive care unit for cardiac insufficiency not drug related, one consent withdrawn). Vomiting, despite the use of anti-emetic therapy, was noted frequently during conditioning therapy which corresponded to the first week of itraconazole treatment. However, four patients also had frequent vomiting after this period. All patients developed mucositis stage 2 to 4 and mild diarrhea persisting up to the end of the neutropenia (Table 1) . No patient developed acute GVHD nor systemic aspergillosis during itraconazole treatment.
Average drug concentration-time curves with the residual (C min ) and peak (C max ) plasma concentrations of unchanged ITRA and OH-ITRA from day Ϫ7 to day +7 are plotted in Figures 1 and 2 , respectively. The mean values of C min ITRA and OH-ITRA, respectively, were 287 Ϯ 109 ng/ml and 629 Ϯ 227 ng/ml (n = 10) at day Ϫ1 (after 7 days of itraconazole treatment) and 378 Ϯ 147 ng/ml and 725 Ϯ 242 ng/ml (n = 10) at day +1 (after 9 days of itraconazole treatment). The maximum mean values of C min ITRA and OH-ITRA were observed at day +3.
The relative percentage of patients having an ITRA C min greater than 250 ng/ml during the study is given in Figure  3 . During the pretransplant phase (day Ϫ7 to Ϫ1), residual plasma concentrations of unchanged ITRA reached 250 ng/ml in six out of 11 patients (54%) on day Ϫ1. Low plasma levels were observed in three patients. They were related to intense vomiting resulting in low C max . Effective level of active fraction (sum of ITRA and OH-ITRA) was reached at the 7th day of treatment in five out of 11 patients.
At day +1, eight out of 11 patients (72%) had unchanged ITRA C min levels greater than 250 ng/ml with a C max greater than the C min , six patients presented an active fraction greater than 1000 ng equivalent/ml. From day +1 to +7, plasma concentrations increased or remained unchanged in five patients and decreased in four others. Two patients discontinued their ITRA treatment after day +1.
After day +7, four other patients discontinued treatment before the end of the neutropenia. Among patients who discontinued itraconazole treatment, four had satisfactory residual plasma concentrations at the time of discontinuation (C min : 285 to 576 ng/ml for ITRA and 561 to 973 ng/ml for OH-ITRA).
At day +9, two patients discontinued their treatment with a residual concentration of 137 and 571 ng/ml of ITRA and 328 and 930 ng/ml for OH-ITRA, respectively. Finally, the three last patients continued their itraconazole treatment up to the end of neutropenia but with insufficient plasma levels: one from day +3, one from day +1, both clearly related to vomiting and one without sufficient active antifungal concentration during the experiment except on day +9.
Values of the metabolic ratio fluctuated from 2.61 Ϯ 0.43 (mean Ϯ s.d.) at day Ϫ5 (n = 10) to 2.23 Ϯ 0.39 at day Ϫ1 (n = 10) and from 1.98 Ϯ 0.32 at day +1 (n = 10) to 2.07 Ϯ 0.48 at day +7 (n = 8).
Discussion
This work is the first pharmacokinetic study of itraconazole oral solution in patients undergoing allogeneic BMT after conditioning including TBI. This study was performed after a previous study on healthy volunteers (J Barone, RH Bierman, Janssen Research Foundation, data on file). These patients have important problems of drug absorption thought to be due to chemotherapy-and radiotherapyinduced damages to the intestinal epithelium. 11 With this oral itraconazole form, six out of 11 patients (54%) had reached a 'therapeutic' level of unchanged ITRA at day Ϫ1, after 7 days of itraconazole treatment, with an average of 363 Ϯ 48 ng/ml for the C min and 696 Ϯ 46 ng/ml for the C max .
Prentice et al 12 have shown that relatively high serum concentrations of itraconazole (C min 394 Ϯ 110 ng/ml and C max 723 Ϯ 217 ng/ml after 8 days of treatment for six patients) can be achieved in bone marrow autograft recipients receiving oral itraconazole solution administered at 2.5 mg/kg twice daily dosages. However this trial differs from ours by the fact that itraconazole treatment was given twice daily, started 3 days after the day of transplant and that the conditioning regimen did not include TBI, inducing probably less vomiting and mucositis. In Prentice's study, after 8 days of itraconazole treatment, itraconazole concentrations continue to increase progressively to reach 845 Ϯ 221 ng/ml and 937 Ϯ 326 ng/ml after 15 and 22 days of antifungal treatment, respectively, while in our study plasma concentrations remain stable or decrease slightly after 9 days of treatment (day +1 posttransplant) and show a marked decrease after 15 days of treatment (day +7). This decrease observed in our series is more likely to be related to a decrease in itraconazole absorption rather than an increase in its metabolism, as the metabolic ratio [OH-ITRA]/[ITRA] remains unchanged. Similar results to those obtained in autologous recipients were observed in patients receiving chemotherapy for acute myeloid leukaemia. 13 We have previously found 14 that itraconazole doses of 600 mg daily as capsules were needed to achieve a therapeutic level in neutropenic patients, including autologous BMT patients receiving no TBI during conditioning, with C min of itraconazole measured after 6 days of treatment comparable to those observed in our present trial with 400 mg daily oral solution formulation. After 9 days of treatment at a 400 mg dosage, we observed with the oral solution 72% of patients achieving a satisfactory level of unchanged ITRA vs, in our previous study, 55% (five out of nine patients) with the capsule formulation. These results suggest an improvement of the bioavailability of itraconazole in oral solution. This is also evident when comparing our data with those provided by Heykants et al 15 and Kintzel et al 16 in allogeneic BMT patients treated with itraconazole 200 mg daily as capsules or itraconazole suspension formulations where itraconazole concentrations were extremely low.
Among the factors influencing absorption, vomiting occurring, despite the use of antiemetic therapy, within 1 h after itraconazole intake influences absorption. During the last phase of our study, the apparent decrease in bioavailability of itraconazole oral solution seems unrelated to coadministration of antacid drugs as shown by comparing itraconazole concentrations after 9 days of treatment: 416 Ϯ 121 ng/ml in patients receiving antacids vs 320 Ϯ 182 ng/ml in patients not receiving antacids.
Mucositis starting in all patients between days +2 to +6 after BMT may probably also have contributed to decreased plasma levels during post-BMT phases. However the number of patients still in the study at these phases is not sufficient to draw a final conclusion on the role of mucositis on itraconazole oral solution absorption. Nevertheless, severity of mucositis could explain the discrepancies observed between some results obtained in the Prentice trial 12 and in our series. In conclusion, our study shows an improvement of plasma levels of ITRA and OH-ITRA in allogeneic BMT patients, suggesting an improvement of the bioavailability when the drug is administered as an oral solution. In 72% of cases, concentrations reach a satisfactory level 9 days after initiation of treatment, indicating that treatment should be started before or at least during the conditioning period. Mean plasma levels were within the therapeutic range up to 15 days of treatment. After this time, plasma levels were low but the small number of patients at the end of the study does not allow us to a draw conclusion on absorption and on the possible role of mucositis at that time. Further studies should be performed to evaluate absorption after the first week post-transplant. Effectively, the highest incidence of fungal infections and occurrence of acute GVHD begin from the second week of aplasia. Therefore more data are needed to evaluate the absorption of ITRA in late phases after BMT.
